Skip to main content
. 2023 Dec 7;12(24):21592–21604. doi: 10.1002/cam4.6693

FIGURE 3.

FIGURE 3

(A) Overall survival, (B) disease‐free survival, (C) recurrence rate, and (D) non‐relapse mortality for ELN favorable ETO‐AML according to different consolidation treatments.